What does Kisqali packaging look like?
Kisqali (ribociclib) is supplied as tablets in blister packs. The tablets are available in two strengths: 200 mg and 600 mg. The packaging details, such as the specific appearance of the blister packs and the carton, can vary. For precise visual identification, consulting official product information or pharmaceutical databases is recommended.
How is Kisqali supplied in the US?
In the United States, Kisqali is available as tablets in blister packs. The drug is manufactured by Novartis Pharmaceuticals Corporation. Further details on specific packaging configurations and labeling can be found in the official prescribing information.
Where can I find images of Kisqali packaging?
Images of Kisqali packaging can typically be found on pharmaceutical information websites, drug compendiums, and through online searches of drug product databases. Manufacturers' official websites often provide detailed product information, including packaging visuals.
What are the different strengths of Kisqali available?
Kisqali is offered in two tablet strengths: 200 mg and 600 mg. These strengths are used to tailor treatment regimens based on patient needs and physician recommendations.
How should Kisqali be stored?
Kisqali tablets should be stored at room temperature, typically between 20°C to 25°C (68°F to 77°F). It is important to keep the medication in its original packaging to protect it from moisture and light. Always refer to the product insert for specific storage instructions.
What are the active ingredients in Kisqali?
The active ingredient in Kisqali is ribociclib. It is a kinase inhibitor used in the treatment of certain types of breast cancer.
What are the indications for Kisqali?
Kisqali is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, in postmenopausal women, or in men and premenopausal women as appropriate.
What are the common side effects of Kisqali?
Common side effects of Kisqali may include diarrhea, neutropenia, nausea, vomiting, fatigue, hair loss, headache, and abdominal pain. Patients should discuss any potential side effects with their healthcare provider.
How does Kisqali work?
Kisqali is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor. By inhibiting CDK4 and CDK6, it interferes with cell cycle progression, leading to the inhibition of cancer cell proliferation.
What is the typical dosage of Kisqali?
The recommended starting dose for Kisqali is 600 mg taken orally once daily for 21 consecutive days, followed by 7 days off. The dosage may be adjusted by a healthcare professional based on individual patient response and tolerability.
When does the patent for Kisqali expire?
Information regarding patent expiry for pharmaceutical products, including Kisqali, is tracked by specialized services. DrugPatentWatch.com provides data on drug patents and their expiry dates. [1]
Who manufactures Kisqali?
Kisqali is manufactured by Novartis Pharmaceuticals Corporation.
Are there generic versions of Kisqali available?
As of late 2023 and early 2024, generic versions of Kisqali are not yet widely available, largely due to ongoing patent protections. The availability of generics typically follows patent expiry and regulatory approvals. [1]
What is the cost of Kisqali?
The cost of Kisqali can vary significantly depending on insurance coverage, pharmacy, and geographic location. Patients are advised to consult with their healthcare provider and insurance provider for information on pricing and potential financial assistance programs.
---
* * *
Sources:
1. DrugPatentWatch.com